Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Roflumilast: a guide to its use in chronic obstructive pulmonary disease

    • 97 Accesses

    This is a preview of subscription content, log in to check access.

    Table I
    Table II
    Fig 1

    References

    1. 1.

      Sanford M. Roflumilast: in chronic obstructive pulmonary disease. Drugs 2010; 70(12): 1615–27

    2. 2.

      Daxas 500 micrograms film-coated tablets: summary of product characteristics. London; European Medicines Agency, 2011 May 3

    3. 3.

      Daliresp™ (roflumilast) tablets: US prescribing information. St Louis (MO); Forest Laboratories, Inc., 2011 Feb

    4. 4.

      Bethke TD, Huennemeyer A, Lahu G, et al. Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults. Chronobiol Int 2010 Oct; 27(9–10): 1843–53

    5. 5.

      de Mey C, Nassr N, Lahu G. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study. BMC Clin Pharmacol 2011 Jun 1; 11: 7

    6. 6.

      Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005 Aug 13; 366(9485): 563–71

    7. 7.

      Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res 2011 Jan 27; 12(1): 18

    8. 8.

      Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 M 15; 176(2): 154–61

    9. 9.

      Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009 Aug 29; 374(9691): 685–94

    10. 10.

      Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009 Aug 29; 374(9691): 695–703

    11. 11.

      Calverly P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449–56

    12. 12.

      Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting β2 agonists for COPD: influence of exacerbation history. Eur Respir J. Epub 2011 Jul 7

    13. 13.

      Hansel TT, Barnes JJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 2009 Aug 29; 374(9691): 744–55

    14. 14.

      Mills EJ, Druyts E, Ghement I, et al. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011 Mar 28; 3: 107–29

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Roflumilast: a guide to its use in chronic obstructive pulmonary disease. Drugs Ther. Perspect 27, 6–10 (2011). https://doi.org/10.2165/11206470-000000000-00000

    Download citation